Postoperative melagatran/ximelagatran for the prevention of venous thromboembolism following major elective orthopaedic surgery: Effects of timing of first dose and risk factors for thromboembolism and bleeding complications on efficacy and safety

Clinical Drug Investigation

Volumn 25, Issue 1, 2005, Pages 65-77

  Dahl, Ola E ^a   Eriksson, Bengt I ^b   Agnelli, Giancarlo ^c   Cohen, Alexander T ^d   Mouret, Patrick ^e   Rosencher, Nadia ^f   Panfilov, Seva ^g   Bylock, Anders ^g   Andersson, Magnus ^g  

^a THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF PERUGIA   (Italy)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e Frankfurt Höchst City Hospital   (Germany)

^f Cochin Hospital ^*  (France)

^g ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; XIMELAGATRAN;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ELECTIVE SURGERY; EUROPE; FEMALE; HUMAN; INTRAOCULAR HEMORRHAGE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MAJOR SURGERY; MALE; MULTICENTER STUDY; ORTHOPEDIC SURGERY; POSTOPERATIVE PERIOD; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REOPERATION; RETROPERITONEAL HEMORRHAGE; RISK FACTOR; SPINAL CORD HEMORRHAGE; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 11244335740     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200525010-00006     Document Type: Article

References (27)

1. Turpie AG, Chin BS, Lip GY. ABC of antithrombotic therapy. Venous thromboembolism: pathophysiology, clinical features, and prevention. BMJ 2002; 325: 887-90
2. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001; 119: 132-75S
3. Koehn H, Koenig B, Mostbeck A. Incidence and clinical features of pulmonary embolism in patients with deep vein thrombosis: a prospective study. Eur J Nucl Med 1987; 13: S11-5
4. Committee for Proprietary Medicinal Products, European Agency for the Evaluation of Medicinal Products. Points to consider on clinical investigation of medicinal products for prophylaxis of intra- and post-operative venous thromboembolic risk. European Agency for the Evaluation of Medicinal Products 2000. Available from URL: http://www.emea.eu.int/pdfs/human/ewp/070798en.pdf [Accessed March 2004]
5. Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119 (1 Suppl.): 8-21S
6. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001; 119: 176-93S
7. Eriksson UG, Bredberg U, Gislen K, et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol 2003; 59: 35-43
8. Johansson S, Wåhlander K, Larson G, et al. Pharmacokinetics and anticoagulant effect of the direct thrombin inhibitor melagatran following subcutaneous administration to young healthy men. Blood Coagul Fibrinolysis 2003; 14: 677-84
9. Eriksson BI, Bergqvist D, Kälebo P, et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002; 360: 1441-7
10. Eriksson BI, Agnelli G, Cohen AT, et al. METHRO III Study Group. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO III study. Thromb Haemost 2003; 89: 288-96
11. Eriksson BI, Agnelli G, Cohen AT, et al. on behalf of the EXPRESS Study Group. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003; 1: 1490-6
12. Heit JA, Colwell CW, Francis CW, et al. for the AstraZeneca Arthroplasty Study Group. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med 2001; 161: 2215-21
13. Francis CW, Davidson BL, Berkowitz SD, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind trial. Ann Intern Med 2002; 137: 648-55
14. Colwell JrC, Berkowitz SD, Davidson BL, et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement: a randomized, double-blind study. J Thromb Haemost 2003; 1: 2119-30
15. Francis CW, Berkowitz SD, Comp PC, et al. EXULT A Study Group. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement: EXULT A. N Engl J Med 2003; 349: 1703-12
16. Colwell CW, Berkowitz SD, Comp PC, et al. and EXULT B Investigators. Randomized, double-blind comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR): EXULT B [abstract 39]. Blood 2003; 102: 14a
17. Cohen AT, Agnelli G, Dahl OE, et al. Efficacy and safety of the treatment regimen of melagatran and ximelagatran for prevention of thromboembolic events after total hip or knee replacement: a meta-analysis of 3 randomized, double-blind studies, to evaluate the influence of time and dose [abstract]. J Thromb Haemost 2003; 1 Suppl. 1: P1915
18. Raskob GE, Hirsh J. Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. Chest 2003; 124 (6 Suppl.): 379-85S
19. Dahl OE, Bergqvist D. Current controversies in deep vein thrombosis prophylaxis after orthopaedic surgery. Curr Opin Pulm Med 2002; 8: 394-7
20. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993; 95: 315-28
21. Bullingham A, Strunin L. Prevention of postoperative venous thromboembolism. Br J Anaesth 1995; 75: 622-30
22. Salvati EA. Multimodal prophylaxis of venous thrombosis. Am J Orthop 2002; 3 (9 Suppl.): 4-11
23. Rodgers A, Walker N, Schug S, et al. Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials. BMJ 2000; 321: 1493-504
24. Narchi P. Spinal anaesthesia and the use of anticoagulants. Best Pract Res Clin Anaesthesiol 2003; 17: 443-9
25. Callander CC. Epidural haematoma may occur after epidural and spinal regional anaesthesia [letter]. BMJ 1999; 319: 575
26. Johansson LC, Frison L, Logren U, et al. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet 2003; 42: 381-92
27. Sarich TC, Teng R, Peters GR, et al. No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor, ximelagatran. Clin Pharmacokinet 2003; 42: 485-92